


# Study identifies a potential therapeutic target for triple-negative breast cancer in Black patients

February 21 2023, by Adam Pope



Protein diversity due to alternative mRNA splicing or post-translational modifications (PTMs) plays a vital role in various cellular functions. The mitotic kinases polo-like kinase 1 (PLK1) and Aurora B (AURKB) phosphorylate

survivin, an inhibitor of apoptosis (IAP) family member, thereby regulating cell proliferation. PLK1, AURKB, and survivin are overexpressed in triple-negative breast cancer (TNBC), an aggressive breast cancer subtype. TNBC is associated with high proliferative capacity, high rates of distant metastasis, and treatment resistance. The proliferation-promoting protein survivin and its activating kinases, PLK1 and AURKB, are overexpressed in TNBC. In this study, we investigated the role of survivin phosphorylation in racial disparities in TNBC cell proliferation. Analysis of TCGA TNBC data revealed higher expression levels of PLK1 ( $P = 0.026$ ) and AURKB ( $P = 0.045$ ) in African Americans (AAs;  $n = 41$ ) than in European Americans (EAs;  $n = 86$ ). In contrast, no significant racial differences in survivin mRNA or protein levels were observed. AA TNBC cells exhibited higher p-survivin levels than EA TNBC cells. Survivin silencing using small interfering RNAs significantly attenuated cell proliferation and cell cycle progression in AA TNBC cells, but not in EA TNBC cells. In addition, PLK1 and AURKB inhibition with volasertib and barasertib significantly inhibited the growth of AA TNBC xenografts, but not of EA TNBC tumors. These data suggest that inhibition of PLK1 and AURKB suppresses cell proliferation and tumor growth, specifically in AA TNBC. These findings suggest that targeting survivin phosphorylation may be a viable therapeutic option for AA patients with TNBC. Credit: *Cell Death & Disease* (2023). DOI: 10.1038/s41419-022-05539-5

A new study published in the journal *Cell Death & Disease* by researchers at the University of Alabama at Birmingham has identified a potential therapeutic target for triple-negative breast cancer, or TNBC, an aggressive treatment-resistant breast cancer subtype that disproportionately affects Black women.

This novel study offers a previously unrecognized lens to evaluate disparate racial burden in TNBC. The research team found that post-translational modifications, or PTMs, such as phosphorylation may drive [proliferation](#) and [tumor growth](#) disparately and contribute to differences in racially distinct TNBC.

The study looked at two proteins, PLK1 and AURKB, which are often overexpressed in TNBC, an aggressive type of breast cancer. These proteins help regulate how fast cancer cells grow and divide by regulating the activation of a proliferation-promoting protein called survivin through phosphorylation.

The researchers found that Black women with TNBC had higher levels of PLK1 and AURKB compared to European American, or EA, women with TNBC. Although total survivin levels were similar between the two groups, the research team showed that activated (phosphorylated) survivin levels were higher in Black women than in EA women with TNBC.

"Black women are disproportionately affected by TNBC, [treatment options](#) for which remain limited," said Ritu Aneja, Ph.D., professor and associate dean for Research and Innovation at the UAB School of Health Professions, and the corresponding author of the study.

"Our findings suggest that pharmacological inhibition of PLK1 and AURKB may be a viable therapeutic option for Black women with TNBC. This is the first study to show a mechanistic basis of racial disparity in an aggressive form of breast cancer and opens a new avenue for the investigation of the biological basis of racial disparities."

The researchers provide the precise molecular mechanism of higher proliferation of Black women with TNBC through the unusual lens of PTM. The research team showed that [racial differences](#) in the levels of PLK1 and AURKB contributed to the higher levels of phosphorylated survivin and faster proliferation of TNBC cells in Blacks compared to those in EA women.

Notably, pharmacological inhibition of both PLK1 and AURKB reduced tumor proliferation significantly in xenograft mice models bearing Black

TNBC tumors than those bearing EA TNBC tumors.

By understanding the role of PTMs, scientists may be able to develop new treatments that can target them and reduce proliferation of TNBC cells. This study highlights the importance of understanding beyond the central dogma of molecular biology to help develop personalized treatments for TNBC patients.

Chakravarthy Garlapati and Shriya Joshi are lead authors of the paper.

**More information:** Chakravarthy Garlapati et al, PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer, *Cell Death & Disease* (2023). [DOI: 10.1038/s41419-022-05539-5](https://doi.org/10.1038/s41419-022-05539-5)

Provided by University of Alabama at Birmingham

Citation: Study identifies a potential therapeutic target for triple-negative breast cancer in Black patients (2023, February 21) retrieved 19 May 2023 from <https://medicalxpress.com/news/2023-02-potential-therapeutic-triple-negative-breast-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.